



Muscular Dystrophies: Pathophysiology and Therapy

Guest Editors:

Dr. France Piétri-Rouxel

Dr. Sestina Falcone

Prof. Dr. Edoardo Malfatti

Deadline for manuscript
submissions:

closed (10 December 2022)

Message from the Guest Editors

This Special Issue, "Muscular Dystrophies: Pathophysiology and Therapy", will focus on the pathophysiological mechanisms underlying muscular dystrophies, new animal models and methodological approaches for studying muscle dysfunction/recovery, as well as the development of innovative therapeutic strategies and ongoing clinical trials.

Therapeutic strategies that address the root cause of these diseases are currently being developed for a handful of muscular dystrophies, including virus-based gene therapy and antisense drugs. In this context, the activation of the host immune system against the transgene or viral capsid, the route of administration and the accurately targeted tissue, in order to achieve the restoration of fully functional muscle in patients, remains a challenge. Therefore, strategies that aim to rescue altered proteins, as well as animal models and methodologies, must be optimized. These must be improved to achieve robust readouts, allowing the validation of treatment efficacy in clinical trials. This Special Issue is open to research studies, ranging from basic to preclinical approaches, and will also cover original articles and reviews.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)